Micafungin Completed Phase 2 Trials for Allogeneic Stem Cell Transplant / Leukemia Acute Myeloid Leukemia (AML) / Myelo Dysplastic Syndrome / Acute Graft Versus Host Disease Grade II-IV Other

clinicaltrials.gov IdentifierTitleDrugs
NCT02172768Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease